Munich - Delayed Quote EUR

Harvard Bioscience Inc (HBI.MU)

0.4380

-0.0020

(-0.45%)

At close: June 13 at 5:25:00 PM GMT+2

Harvard Bioscience Appoints John Duke to Board of Directors

HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. “We are pleased to welcome John to Harvard Bioscience’s board,” said Katherine Eade, Lead I

GlobeNewswire 12 days ago

HBIO
Harvard Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Harvard Bioscience ( NASDAQ:HBIO ) First Quarter 2025 Results Key Financial Results Revenue: US$21.8m (down 11% from 1Q...

Simply Wall St. 30 days ago

HBIO
Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark

Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China tariffs, NIH funding, and biopharmaceutical research activity, which leads the firm to lower its 2025 revenue estimate as a result. However, despite the near-term uncertainty, management remains optimistic about the 2025 prospects for newly launc

TipRanks last month

HBIO
Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite revenue declines and a significant goodwill impairment charge, Harvard Bioscience Inc (HBIO) focuses on new product launches and improved cash flow to drive future growth.

GuruFocus.com last month

HBIO
Harvard Bioscience: Q1 Earnings Snapshot

HBIO) on Monday reported a loss of $50.3 million in its first quarter. The Holliston, Massachusetts-based company said it had a loss of $1.14 per share. Losses, adjusted for one-time gains and costs, were 1 cent per share.

Associated Press Finance last month

HBIO
What Is Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Price Doing?

While Harvard Bioscience, Inc. ( NASDAQ:HBIO ) might not have the largest market cap around , it saw significant share...

Simply Wall St. last month

HBIO
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-onl

GlobeNewswire last month

HBIO
Harvard Bioscience Announces CFO Transition

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q, which is expected to be filed on or before May 12, 2025. The Company has appointed Mark Frost as its Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignatio

GlobeNewswire 2 months ago

HBIO
Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Key Insights Harvard Bioscience's estimated fair value is US$0.35 based on 2 Stage Free Cash Flow to Equity Current...

Simply Wall St. 2 months ago

HBIO
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations

Harvard Bioscience ( NASDAQ:HBIO ) Full Year 2024 Results Key Financial Results Revenue: US$94.1m (down 16% from FY...

Simply Wall St. 3 months ago

HBIO
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day

GlobeNewswire 3 months ago

HBIO
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As

GlobeNewswire 3 months ago

HBIO
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivityHOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing preclinical research and organoid-b

GlobeNewswire 3 months ago

HBIO
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the aud

GlobeNewswire 3 months ago

HBIO
Sidoti Events, LLC's Virtual January Micro-Cap Conference

Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 22-23, 2025. The presentation schedule is subject ...

ACCESS Newswire 4 months ago

SBC

SBCWW

FLXS
One Harvard Bioscience Insider Raised Their Stake In The Previous Year

From what we can see, insiders were net buyers in Harvard Bioscience, Inc.'s ( NASDAQ:HBIO ) during the past 12 months...

Simply Wall St. 4 months ago

HBIO
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference

HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscienc

GlobeNewswire 4 months ago

HBIO
3 US Penny Stocks With Market Caps Under $100M

As U.S. stocks experience fluctuations amid anticipation of key inflation data and interest rate decisions, investors are keenly observing market movements for potential opportunities. Penny stocks, a term that may seem outdated, continue to capture attention due to their affordability and growth potential, particularly when backed by strong financials. These smaller or newer companies can offer unique value propositions that larger firms might overlook, making them intriguing options for...

Simply Wall St. 6 months ago

HBIO

HLVX

CYCN
Harvard Bioscience Third Quarter 2024 Earnings: Misses Expectations

Harvard Bioscience ( NASDAQ:HBIO ) Third Quarter 2024 Results Key Financial Results Revenue: US$22.0m (down 13% from 3Q...

Simply Wall St. 7 months ago

HBIO
Harvard Bioscience Inc (HBIO) Q3 2024 Earnings Call Highlights: Navigating Challenges and ...

Despite a revenue decline, Harvard Bioscience Inc (HBIO) focuses on innovative products and operational efficiencies to drive future growth.

GuruFocus.com 7 months ago

HBIO

Performance Overview

Return	HBI.MU	S&P 500 (^GSPC)
YTD	-76.07%	+1.62%
1-Year	-83.78%	+10.00%
3-Year	-88.03%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Harvard Bioscience Inc (HBI.MU)

Harvard Bioscience Appoints John Duke to Board of Directors

Harvard Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Harvard Bioscience price target lowered to $3 from $4.50 at Benchmark

Harvard Bioscience Inc (HBIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Harvard Bioscience: Q1 Earnings Snapshot

What Is Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Price Doing?

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

Harvard Bioscience Announces CFO Transition

Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

Sidoti Events, LLC's Virtual January Micro-Cap Conference

One Harvard Bioscience Insider Raised Their Stake In The Previous Year

Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference

3 US Penny Stocks With Market Caps Under $100M

Harvard Bioscience Third Quarter 2024 Earnings: Misses Expectations

Harvard Bioscience Inc (HBIO) Q3 2024 Earnings Call Highlights: Navigating Challenges and ...

Performance Overview